The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Parminder K Judge, Katherine R Tuttle, Natalie Staplin, Sibylle J Hauske, Doreen Zhu, Rebecca Sardell, Lisa Cronin, Jennifer B Green, Nikita Agrawal, Ryoki Arimoto, Kaitlin J Mayne, Emily Sammons, Martina Brueckmann, Shimoli V Shah, Peter Rossing, Masaomi Nangaku, Martin J Landray, Christoph Wanner, Colin Baigent, Richard Haynes, William G Herrington

Open source

DOI: 10.1093/ndt/gfae263
Published: 2024-11-12
Container: Nephrology Dialysis Transplantation
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ndt/gfae263,
  title = {The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial},
  author = {Parminder K Judge and Katherine R Tuttle and Natalie Staplin and Sibylle J Hauske and Doreen Zhu and Rebecca Sardell and Lisa Cronin and Jennifer B Green and Nikita Agrawal and Ryoki Arimoto and Kaitlin J Mayne and Emily Sammons and Martina Brueckmann and Shimoli V Shah and Peter Rossing and Masaomi Nangaku and Martin J Landray and Christoph Wanner and Colin Baigent and Richard Haynes and William G Herrington},
  year = {2024},
  journal = {Nephrology Dialysis Transplantation},
  doi = {10.1093/ndt/gfae263},
  url = {https://doi.org/10.1093/ndt/gfae263}
}

RIS

TY  - JOUR
TI  - The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
AU  - Parminder K Judge
AU  - Katherine R Tuttle
AU  - Natalie Staplin
AU  - Sibylle J Hauske
AU  - Doreen Zhu
AU  - Rebecca Sardell
AU  - Lisa Cronin
AU  - Jennifer B Green
AU  - Nikita Agrawal
AU  - Ryoki Arimoto
AU  - Kaitlin J Mayne
AU  - Emily Sammons
AU  - Martina Brueckmann
AU  - Shimoli V Shah
AU  - Peter Rossing
AU  - Masaomi Nangaku
AU  - Martin J Landray
AU  - Christoph Wanner
AU  - Colin Baigent
AU  - Richard Haynes
AU  - William G Herrington
PY  - 2024
JO  - Nephrology Dialysis Transplantation
DO  - 10.1093/ndt/gfae263
UR  - https://doi.org/10.1093/ndt/gfae263
ER  -

APA

Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., Mayne, K. J., Sammons, E., Brueckmann, M., Shah, S. V., Rossing, P., Nangaku, M., Landray, M. J., Wanner, C., Baigent, C., Haynes, R., & Herrington, W. G. (2024). The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae263

Source records

crossref · retrieved 2026-09-27T03:38:07.014Z